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The expression of genes involved in the pathogenesis of Staphylococcus aureus is known to be controlled by
global regulatory loci, including agr, sarA, sae, arlRS, lytSR, and sarA-like genes. Here we described a novel
transcriptional regulator called sarV of the SarA protein family. The transcription of sarV is low or undetect-
able under in vitro conditions but is significantly augmented in sarA and mgrA (norR or rat) (SA0641) mutants.
The sarA and mgrA genes act as repressors of sarV expression, as confirmed by transcriptional fusion and
Northern analysis data. Purified SarA and MgrA proteins bound specifically to separate regions of the sarV
promoter as determined by gel shift and DNase I footprinting assays. The expression of 19 potential target
genes involved in autolysis and virulence, phenotypes affected by sarA and mgrA, was evaluated in an isogenic
sarV mutant pair. Our data indicated that the sarV gene product played a role regulating some virulence genes
and more genes involved in autolysis. The sarV mutant was more resistant to Triton X-100 and penicillin-
induced lysis compared to the wild type and the sarA mutant, whereas hyperexpression of sarV in the parental
strain or the sarV mutant rendered the resultant strain highly susceptible to lysis. Zymographic analysis of
murein hydrolase activity revealed that inactivation of the sarV gene results in decreased extracellular murein
hydrolase activity compared to that of wild-type S. aureus. We propose that sarV may be part of the common
pathway by which mgrA and sarA gene products control autolysis in S. aureus.
Staphylococcus aureus is an important human pathogen that
has become a growing public health concern, primarily due to
the emergence of antibiotic-resistant strains within the hospital
environment (4, 5, 25). The spectrum of infections caused by
this organism is extremely broad, ranging from cutaneous in-
fections such as impetigo, folliculitis, and carbuncles to deep-
seated infections such as pneumonia, endocarditis, septicemia,
osteomyelitis, and other metastatic complications. Besides in-
vasion syndromes, S. aureus can also cause toxin-mediated
diseases such as food poisoning, toxic shock syndrome, and
scalded skin syndrome. The primary site of infection is gener-
ally the skin or a wound from which the organism can spread
to the bloodstream and subsequently disseminate into various
host tissues. Once S. aureus establishes its presence in the
tissue, it produces a large number of bacterial components and
secreted products that include surface-associated protein ad-
hesins, enzymes, exotoxins, and capsular polysaccharides, gene
products that facilitate tissue colonization, tissue destruction,
and immune evasion. The expression of many of these genes is
coordinately controlled by regulatory loci (2, 5, 33, 35). These
regulatory loci include agr, sarA, saeRS, sigB, lytSR, arlRS, and
sarA-like genes.
The agr locus consists of two divergent transcripts, RNAII
and RNAIII, which encode agrDBCA and hld, respectively (19,
20, 33). It is also a complex quorum-sensing two-component
regulatory system in S. aureus. The RNAII transcriptional unit
codes for four genes, of which agrBD are involved in the gen-
eration and secretion of an autoinducing octapeptide. As the
autoinducing peptide reaches a threshold concentration in the
growth medium during the transition from exponential to pos-
texponential phase, activation of agrC and agrA, encoding the
two-component regulatory system, would occur, leading to the
transcription of RNAII and RNAIII, the agr regulatory mole-
cule responsible for the up-regulation of exoproteins and
down-regulation of cell wall-associated proteins (20, 33). The
sarA locus comprises a major open reading frame (ORF), sarA,
driven by three distinct promoters, resulting in three overlap-
ping transcripts with a common terminating end (8, 29). The
sarA locus up-modulates the expression of selected cell wall
proteins and exoproteins (e.g., - and -hemolysins). DNA
binding studies have revealed that SarA, the major sarA effec-
tor molecule, binds to several target gene promoters (e.g., agr,
hla, and spa) to modulate gene transcription (10), thus impli-
cating both agr-dependent and agr-independent pathways for
SarA-mediated regulation.
Using affinity chromatography and genomic scan, we and
others have identified several SarA homologs that are involved
directly or indirectly in gene regulation. SarR, a 115-residue-
long polypeptide (30), represses SarA expression during the
postexponential phase by binding to the sarA promoter region.
SarS (also called SarH1) is a 250-residue protein (9, 44) re-
pressed by agr to activate spa expression and, to a lesser extent,
to down-regulate hla expression. rot, also a sarA homolog, is a
negative regulator for hemolysins (hla and hlb), lipase (geh),
and serine proteases (sspB and splA) as well as a positive
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regulator for cell surface proteins (clfB/clumping factor, spa/
protein A, sdrC/putative cell surface adhesin) (32, 39). SarT is
a repressor of hla and RNAIII transcription (41). Contiguous
to sarT, but transcribed in the opposite orientation, is sarU
(sarH2), whose expression is negatively controlled by SarT.
Phenotypic and transcriptional analysis revealed that sarU is a
positive regulator of RNAIII and contributes to the expression
of virulence genes controlled by agr (31). More recently, mgrA
(also called rat or norR), a homolog of marR and also sarA, has
been found to negatively regulate autolysis genes without sig-
nificantly affecting sarA and agr expression (17). The mgrA
gene also impacts upon the expression of type 8 capsular poly-
saccharide (cap8), -hemolysin (hla), protein A (spa), norA,
lipase, protease, and coagulase (27, 45).
Besides regulating virulence genes, the agr and sarA loci are
also involved in the regulation of genes involved in the autol-
ysis process, but the exact mechanism (e.g., direct versus indi-
rect) is not known. Two-component regulatory systems such as
ArlRS and LytSR have been shown to participate in the reg-
ulation of autolysis genes (6, 12, 13, 16). Downstream of the
dicistronic lytSR operon is the lrgAB locus, the expression of
which is dependent on activation by LytSR. Based on homol-
ogy alone, it has been speculated that LrgA may function as an
antiholin to inhibit murein hydrolase activity, presumably by
interfering with the holin molecule that has been postulated to
form a pore for the transport of murein hydrolases across the
cell membrane (4, 7, 14). Although the exact mechanism of
autolysis and their mode of regulation are not well defined, it
is hypothesized that a diminution in transport of autolysins
across the cell membrane would reduce the autolytic process.
We have identified another homolog of SarA, a 116-residue-
long polypeptide called SarV (SA2062 and protein GI13702067)
(21). The expression of sarV is repressed by sarA and mgrA
(SA0641 and protein GI 13700577), known to be involved in
the control of virulence and autolysis genes. Inactivation of
sarV did not affect the expression of regulatory genes such as
sarU, sarR, sarS, sarT, sarA, rot, and sae but had discernible
effects on the expression of agr RNAII and RNAIII, lytSR, and
arlRS. As sarA and mgrA are involved in the regulation of
autolysis and virulence genes, we also evaluated the expression
of 19 potential target genes involved in these phenotypes (33)
(spa, coa, clfA, fnbA, fnbB, hla, atl, lytM, lytN, lrgAB, geh, scdA,
abcA, pbp4, splA, scp, aur, norA, and cap8) by Northern blot-
ting and transcriptional fusions in sarV mutants. Importantly,
the sarV gene product is involved in the regulation of autolysin
and protease genes (scdA, lrgB, atl, splA, and aur). Lytic assays
with Triton X-100 and penicillin indicated that the sarV mu-
tant, contrary to the effect of mgrA and sarA mutants, is more
resistant to lysis than the parent, while hyperexpression of sarV
renders the strain sensitive. Analysis of the sarV mutant indi-
cated that this gene regulates extracellular and intracellular
murein hydrolase activity, possibly by regulating selective
genes involved for autolysis. Because sarV likely does not reg-
ulate mgrA or sarA, we propose that sarV constitutes an im-
portant “hub” for the control of autolysis by mgrA and sarA.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains and plasmids
used in this study are listed in Table 1. Phage 11 was used as a generalized
transducing phage for S. aureus strains. S. aureus strain RN4220, a restriction-
deficient derivative of strain 8325-4, was used as the initial recipient for the
transformation of plasmid constructs. S. aureus cells were grown at 37°C with
aeration in Trypticase soy broth (TSB) or 03GL agar medium supplemented with
antibiotics when necessary. Luria-Bertani medium was used for growing Esche-
richia coli. Antibiotics were used at the following concentrations: for S. aureus,
erythromycin at 5 g/ml, kanamycin at 50 g/ml, tetracycline at 5 g/ml, and
chloramphenicol at 10 g/ml; for E. coli, ampicillin at 50 g/ml, chloramphenicol
at 30 g/ml, erythromycin at 200 g/ml, and spectinomycin at 75 g/ml.
Genetic manipulations in E. coli and S. aureus. Based on homology with SarA,
the sarV gene product was initially identified in the S. aureus N315 genome
database (21; www.tigr.org/ and www.ncbi.nlm.nih.gov/genomics). To construct a
sarV mutant, the sarV gene together with flanking sequences on both sides were
amplified by PCR with the primers 5-AACTGTCGATGGATTTAACGTTA-3
and 5-AGTTTAGTATTAGGTACAGCGA-3, using chromosomal DNA from
strain RN6390 as the template. The 2.2-kb PCR fragment was cloned into
cloning vector pCR 2.1 (Invitrogen, San Diego, Calif.) in E. coli. The HindIII-
EcoRV DNA fragment containing the 2.2-kb fragment was then cloned into the
HindIII and HincII sites of pUC19. A 565-bp fragment, comprising the sarV
coding region as well as 137 and 78 bp of the respective upstream and down-
stream regions, was deleted by restricting with BsaBI and SphI and then replac-
ing the deleted fragment with a 1.2-kb ermC gene at these sites. The fragment
containing the ermC replacement of the deleted sarV gene was cloned into the
temperature-sensitive shuttle vector pCL52.2. Construction and selection of the
putative sarV mutant (tetracycline-sensitive and erythromycin-resistant colonies)
were performed as described elsewhere (30, 31). A phage 11 lysate of the
putative sarV mutant was then prepared to infect fresh strain RN6390 cells to
reconstruct the sarV mutant, in an attempt to avoid any putative genomic mu-
tations that might have occurred during the temperature shift to promote ho-
mologous recombination. The correct mutation was confirmed by PCR, North-
ern, and Southern hybridization with sarV and ermC probes as described
previously (28, 30). One clone, designated ALC2319, was selected for further
study.
To complement the sarV mutation, a 1.5-kb fragment encompassing the sarV
gene and 295 bp upstream of the sarV translation start site were cloned into
shuttle plasmid pSK236. The recombinant plasmid was electroporated into
RN4220, selecting for chloramphenicol-resistant colonies. The correct transfor-
mant was verified by restriction analysis of the recombinant plasmid. The plasmid
from RN4220 was then electroporated into parental strain RN6390 and the sarV
mutant (ALC2319) to construct strains ALC2375 and ALC2376, respectively.
Isolation of RNA and Northern blot hybridization. Total RNA from S. aureus
was prepared by using a TRIzol isolation kit (Gibco BRL, Gaithersburg, Md.)
and a reciprocating shaker as described elsewhere (8, 30, 31). The optical density
at 650 nm OD650 of various cultures was determined with a spectrophotometer
(Spectronic 20). The concentration of total RNA was determined by measuring
the absorbance at 260 nm, and 10 g of each total RNA sample was analyzed by
Northern blotting as described previously (30). The genes coding for agr RNAII,
agr RNAIII, sarA, sarR, sarT, sarS, sarU, rot, mgrA, sae, lytS, lytR, arlS, arlR, spa,
coa, clfA, fnbA, fnbB, hla, lytM and -N, atl, lrgB, geh, scdA, abcA, pbp4, splA, scp,
aur, norA, and cap8 were either amplified by PCR or excised from the plasmids
containing the desired genes with restriction endonucleases. An internal frag-
ment of the 16S rRNA gene (nucleotides [nt]777 to 1500; GenBank accession no.
X68417) was used as a loading control. For detection of specific transcripts,
gel-purified DNA probes were radiolabeled with [-32P]dCTP by using the ran-
dom-primed DNA labeling kit (Roche Diagnostics GmbH) and hybridized under
aqueous-phase conditions at 65°C. The blots were subsequently washed and
autoradiographed.
Transcriptional fusion studies of agr RNAII, agr RNAIII, hla, sarA, sarV, arlR,
and lytS promoters linked to the gfpuvr reporter gene. Construction of the plas-
mid pALC1743, -1742, and -1740 containing agr RNAIII, agr RNAII, and hla
promoter fragments linked to the gfpuvr reporter gene were described earlier (18,
31). A 268-bp sarV promoter fragment (position 21 to 288 nt upstream from the
start ATG codon) was amplified by PCR using chromosomal DNA of S. aureus
strain RN6390 and primers with flanking EcoRI or XbaI sites. An EcoRI and
XbaI fragment containing the sarV promoter was cloned into shuttle plasmid
pALC1484, generating plasmid pALC2489 containing the transcriptional fusion
of the sarV promoter to the gfpuvr reporter gene. The construction of plasmid
pALC1484 and modification of gfpuv (Clontech, Palo Alto, Calif.) to gfpuvr with
an S65T mutation to yield a red shift (excitation maxima from 395 to 488 nm)
were described earlier (18). Similarly, DNA fragments containing arlS, lytR, and
mgrA P1 promoters were cloned into shuttle plasmid pALC1484, generating
plasmids containing transcriptional fusions to the gfpuvr reporter gene (17).
Restriction analysis and DNA sequencing confirmed the orientation and authen-
ticity of the promoter reporter gene constructs. The recombinant plasmids,
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containing the respective promoter regions, were first introduced into S. aureus
strain RN4220 by electroporation. Plasmids purified from RN4220 transformants
were then electroporated into RN6390, its isogenic sarV::ermC (ALC2319),
sarA::ermC (ALC1342), mgrA::ermC (ALC2530), mgrA::ermC/sarA::kan (ALC2535)
mutants, and single-copy complemented mgrA (ALC2531) and sarA (ALC1629)
strains as required.
After overnight culture, S. aureus strains harboring the recombinant plasmids
were diluted 1:100 in TSB containing chloramphenicol (10 g/ml) and grown at
37°C with shaking at 250 rpm. Aliquots (200 l) were transferred hourly to
microtiter plates to assay for OD650 and fluorescence for 10 h in an FL600
fluorescence reader (BioTek Instrument, Winooski, Vt.). Promoter activation
was plotted as mean fluorescence per OD650 over time, using the average values
from triplicate readings.
Purification of SarA and MgrA proteins. The cloning and purification of the
His6 tagged fusion SarA protein were described earlier (10). The 444-bp DNA
fragments containing the full-length mgrA gene (SA0641of S. aureus N315) were
amplified by PCR using chromosomal DNA from S. aureus RN6390 as the
template and primers containing flanking restriction sites (NdeI and BamHI) to
facilitate in-frame cloning into the expression vector pET14b (Novagen, Madi-
son, Wis.). The recombinant plasmids containing the full-length mgrA coding
region were confirmed by restriction digestion and DNA sequencing. The re-
combinant plasmids were then transformed into E. coli BL21(DE3)pLysS. The
recombinant His6-MgrA protein expression and purification were done in a
manner similar to that for the SarA protein as described elsewhere (10). The
authenticity and purity of the purified His6-tagged MgrA fusion protein were
confirmed by sodium dodecyl sulfate (SDS) gels stained with Brilliant Blue R-250
and microsequenced for the first 20 residues from the N terminus. The purified
His6-tagged SarA and MgrA proteins were found to be more than 98% pure in
an SDS–12% polyacrylamide gel. The concentration of the purified proteins was
determined by the Bradford protein assay (Bio-Rad, Hercules, Calif.), using
bovine serum albumin as the standard.
Gel shift analysis and DNase I footprinting. To determine if the recombinant
SarA or MgrA proteins bind to the sarV promoter region, a 191- or 268-bp
fragment (positions 21 to 211 or 288), representing the sarV promoter region,
was end labeled with [-32P]ATP by using T4 polynucleotide kinase. Labeled
fragment (0.1 ng or 0.5 fmol) was incubated at room temperature (RT) for 20
min with various amounts of purified SarA or MgrA protein in 25 l of binding
buffer (25 mM Tris-Cl [pH 7.5], 0.1 mM EDTA, 75 mM NaCl, 1 mM dithio-
threitol, and 10% glycerol) containing 0.5 g of calf thymus DNA (Amersham
Pharmacia Biotech). The reaction mixtures were analyzed in an 8.0% nondena-
turing polyacrylamide gel. The band shifts were detected by exposing dried gels
to X-ray films.
Footprinting assays with template DNA fragment and DNase I were per-
formed as previously described (3, 10, 30). To label PCR products, only one of
the primers was labeled at one end. For the assay, the binding reactions were
carried out in a 100-l reaction volume containing 20 mM Tris-Cl (pH 8.0), 100
mM NaCl, 5 mM MgCl2, 1 mM CaCl2, 2 mM dithiothreitol, 10 g of bovine
serum albumin, 0.4 g of calf thymus DNA, radiolabeled template DNA (20,000
cpm), and various amounts of the purified SarA or MgrA proteins at RT for 30
min. DNase I (0.02 U; Boehringer, Mannheim, Germany) was added and al-
lowed to incubate for 1 min at RT. The reaction mixtures were extracted with
phenol-chloroform, ethanol precipitated, washed with 70% ethanol, dried, and
resuspended in loading buffer (98% deionized formamide, 10 mM EDTA [pH
8.0], 0.025% [wt/vol] xylene cyanol FF, 0.025% [wt/vol] bromophenol blue).
DNA samples were denatured at 95°C for 5 min and analyzed on a 6% dena-
turing polyacrylamide sequence gel. The positions of the protected region were
derived by comparing the footprint with the AG sequencing ladder of the same
fragment (28).
Primer extension analysis. Mapping of the 5 end of the sarV transcript by
primer extension was performed using the primer 5-CTTCAATTGAAATCTT
ATGTGTTG-3, complementary to the sarV coding strand and located from nt
positions 94 to 71 downstream from the putative start codon ATG. Reverse
TABLE 1. Strains and plasmids used
Strain or plasmid Reference or source Comment
S. aureus strains
RN4220 30 Mutant of 8325-4 that accepts foreign DNA
RN6390 30 Laboratory strain that maintains its hemolytic pattern when propagated on sheep erythrocyte agar
(parental strain)
RN6911 6 agr mutant of RN6390 with an 	agr::tetM mutation
JC1413 43 atl mutant of S. aureus
ALC1342 Laboratory strain A sarA mutant with deletion of ORF3 and the sarA ORF and replaced with an ermC gene,
	orf3sarA::ermC
ALC488 29 sarA mutant of RN6390 with sarA::ermC
ALC1629 Laboratory strain ALC1342 with sarB (nt 1 to 1349 plus 180 bp of upstream sequence) integrated into the geh locus
on the chromosome
ALC1713 30 sarR mutant of RN6390 with 	sarR::ermC
ALC1905 41 sarT mutant of RN6390 with 	sarT::ermC
ALC2272 31 sarU mutant of RN6390 with 	sarU::ermC
ALC1893 9 sarS mutant of RN6390 with 	sarS::ermC
ALC2530 17 mgrA mutant of RN6390 with 	mgrA::ermC
ALC2531 17 ALC2530 complemented with mgrA gene into the geh locus on the chromosome
ALC2319 This study sarV mutant of RN6390 with a deletion of ORF of the sarV gene and replaced with an ermC gene
ALC2375 This study RN6390 with pALC2366
ALC2376 This study ALC2272 with pALC2366
E. coli strains
XL-1 Blue 28 Host strain for cloning
Topo InvF Invitrogen Host strain for the TA cloning vector
Primers
pCL52.2 30 Temperature-sensitive E. coli-S. aureus shuttle vector
pCR2.1 Invitrogen E. coli cloning vector for direct cloning of PCR products
pSK236 31 Shuttle vector containing pUC19 cloned into the HindIII site of pC194
pUC19 28 E. coli cloning vector
pALC1484 18 Modified pSK236 shuttle vector with a promoterless gfpuvr reporter gene preceded by an S. aureus
ribosome binding site
pALC2231 This study pUC19 containing a 2.2-kb EcoRVIHindIII fragment containing sarV gene
pALC2280 This study pCL52.2 containing a 2.84-kb DNA fragment which has a deletion of a 565-bp BsaBl/SphI frag-
ment that includes complete ORF of the sarV gene and an insertion of the 1.2-kb ermC gene at
the BsaBI/SphI sites
pALC2366 This study pSK236 with a 1.4-kb DNA fragment containing the sarV gene with a 295-bp upstream sequence
at the EcoRI site
pALC2489 This study pALC1484 with a 273-bp promoter fragment of sarV fused with the gfpuvr reporter gene at the
EcoRI/XbaI sites
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transcription was carried out as described elsewhere by using total RNA isolated
from wild-type RN6390 or the sarA mutant as described previously (3, 30).
Lytic assays with Triton X-100 and penicillin. These assays were performed as
described elsewhere (12, 17, 27). In brief, overnight-grown bacteria were diluted
to an OD650 of 0.05 in TSB containing 1 M NaCl and allowed to grow at 37°C
with shaking till the OD650 reached 0.7 to 1.2. Cells were harvested, washed twice
with ice-cold water, and then resuspended in 0.05 M Tris-Cl (pH 7.2) in the
original volume with or without 0.05% Triton X-100. Cells were incubated at
30°C with shaking and checked for lysis by measuring the progressive decrease in
absorbance (OD650) at 30-min intervals. To assess the sensitivity of the sarV
mutant to penicillin, inoculations were done in TSB from overnight cultures to
yield a starting OD650 of 0.05. Cultures were grown at 37°C with shaking to reach
exponential phase (OD650 0.5). Penicillin G was added to a concentration of
0.4 g/ml. Cultures were incubated further, and the OD650 was measured every
hour for 7 to 8 h.
Zymographic analysis. For the detection of extracellular and intracellular
murein hydrolases, SDS-polyacrylamide gel electrophoresis-based zymographic
analysis was performed as described by Groicher et al. (16). In brief, various
strains were grown in TSB medium for 16 h at 37°C and 250 rpm. Extracellular
murein hydrolases were isolated by pelleting 16-h cultures at 6,000 
 g for 20 min
at 4°C. The supernatant was filter sterilized and concentrated 100-fold by using
polyethylene glycol 8000, followed by dialysis in phosphate-buffered saline. To
obtain intracellular and cell wall-associated murein hydrolases, the cell pellets
were extracted as essentially described by Groicher et al. (16), and final fractions
were dialyzed against phosphate-buffered saline buffer.
The concentrations of total proteins in each sample were determined by using
the Bradford assay (Bio-Rad) according to the manufacturer’s procedures. Var-
ious protein fractions were resolved on an SDS–12% polyacrylamide gel con-
taining either Micrococcus luteus (Sigma Chemical Co.) or autoclaved and ly-
ophilized S. aureus RN6390 cells (1 mg [dry weight] of cells per ml of gel). After
electrophoresis, gels were washed with water and incubated overnight in 25 mM
Tris-Cl, pH 8.0, containing 1% Triton X-100 at 37°C to allow hydrolysis of the
embedded bacterial cells. After incubation, gels were stained with 1% methylene
blue (Sigma Chemical Co.) and destained in water. Following destaining the gels
were scanned in a scanner, and the white bands in the gels (zones of hydrolysis)
indicated regions of murein hydrolase activity. Quantitative cell wall hydrolysis
assays were performed as described by Rice et al. (38) as the turbidity of the
samples was determined by measuring the absorbance at 580 nm with a spec-
trophotometer.
RESULTS
Identification of the sarV gene. Searching for additional
SarA homologs in the recently published S. aureus N315 ge-
nome, we found at least 12 proteins homologous to SarA
(SA0573, protein GI 13700508), using a default setting of 30 as
the cutoff for the BLAST search (21; www.ncbi.nlm.nih.gov
/genomes/staphylococcus). Some of these homologs included
SarT (SA2286 or SarH3, protein GI 13702448; e-value of
9e17) (41), SarS (also called SarH1 or SA0108, protein GI
13700028; e-value of 1e16) (9, 44), SarU (also called SarH2 or
SA2287, protein GI 13702449; e-value of 2e15) (31), SarR
(SA2089, protein GI 13702095; e-value of 9e12) (30), and Rot
(SA1583, protein GI 13701558; e-value of 0.003) (32). MgrA
(also called Rat, NorR, or SA0641; protein GI 13700577; e-
value of 4e04), more homologous to MarR than to SarA,
has been shown to play a role in the regulation of genes
involved in autolysis and virulence (17, 26, 45). The remain-
ing homologs of unknown function were SA0668 (protein
GI13700559; e-value of 1e04 and 46% homology), SA2174
(protein GI13702335; e-value of 0.002 and 53% homology),
and two more proteins (protein GI 1301144 and 13700062;
e-values of 0.003 and 0.030 and homologies of 48 and 48%
within a small region of proteins, respectively). SarV (SA2062
and protein GI 13702067) is the seventh protein that came up
in our homology search, with SarT, -S, -U, and -R, SA0668,
and MgrA being the first six hits (21). SarV is a 116-residue
polypeptide (13,985 Da) that shares 52, 48, 44, 52, 51, 45, 49,
and 60% homology to SarR, SarA, SarU1 (residues 1 to 124),
SarU2 (residues 125 to 247), SarS1 (residues 1 to 125 of SarS),
SarS2 (residues 126 to 250 of SarS), SarT, and MgrA, respec-
tively. Based on sequence alignment, it can be observed that
specific residues of SarV are conserved within the SarA protein
family, including K23, L36, K48, K80, R82, D86, E87, R88,
Q98, L101, and I109 of SarV (data not shown). In a BLAST
comparison of SarV against other microbial genomes with the
same default setting, we found a number of putative transcrip-
tional regulators with unknown functions (e-values of 2e06 to
9.0). Apart from S. aureus, significant homologs include Bacil-
lus subtilis hypothetical protein ybfA (Z99105; e-value of 2 e04
with 29% identity and 52% similarity) and a probable tran-
scriptional regulator of Clostridium perfringens (AP003188; e-
value of 0.001 with 23% identity and 50% similarity).
Expression of sarV in RN6390 and an assortment of isogenic
mutants. To determine the phenotypic effects of sarV, we con-
structed a sarV mutant in RN6390 by allelic replacement, es-
sentially replacing the sarV gene with an ermC cassette (see
Materials and Methods). A Northern blot assay with a sarV
probe (350 bp) encompassing the coding region disclosed that
sarV was poorly transcribed or undetectable in parental strains
RN6390 and SH1000 (S. aureus 8325-4 rsbU strain; kindly
provided by S. J. Foster). As expected, complementation of the
wild type or the sarV mutant with a plasmid carrying the sarV
gene (ALC2375 or ALC2376) increased the level of transcript
of the sarV gene. Interestingly, the sarV transcript, sizing at
500 nt, was significantly enhanced in two sarA mutants
(ALC488 sarA::ermC and ALC1342 	orf3sarA::ermC) and the
rat/mgrA mutant (	mgrA::ermC), but not in the sarR, sarS,
sarT, sarU, or agr mutants (Fig. 1, top panel). The size of the
transcript also hinted at the monocistronic nature of the sarV
locus. Upon introducing a single copy of the mgrA gene or of
the entire sarB locus into the lipase gene (geh) of the respective
mgrA or sarA mutant (ALC2531 and ALC1629, respectively),
the expression of sarV transcript returned to near the parental
level, suggesting that the expression of sarV is truly repressed
by sarA or the mgrA gene product. To determine whether the
expression of mgrA was affected in these assorted mutants, we
performed Northern analysis with the mgrA probe (450 bp)
and found no significant changes in the expression of mgrA
transcript in agr, sarT, sarU, sarV, sarS, and sarA mutants (Fig.
1, middle panel). The expression of mgrA gene transcript was
slightly elevated in the sarR mutant. Notably, the mgrA tran-
script level was more elevated in strains (ALC2375 and
ALC2376) harboring a multicopy plasmid carrying the sarV
gene. Thus, besides repression by mgrA, it would seem that
increased expression of sarV transcript also enhances mgrA
expression, suggesting that sarV may act as an activator for the
expression of mgrA transcript. However, the significance of this
finding remains unclear, since we do not know the physiologic
relevance of increased gene dosage in vivo (Fig. 1, top panel).
There are no significant growth differences in the growth
curves for the sarV mutant compared with those for the wild
type and various mutants (data not shown). Growth phase
variation of various mutants did not make any difference in the
data presented above for the expression of sarV transcript
when Northern blot hybridization was performed with total
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RNA isolated in the early phase of growth of various mutants
(data not shown).
Transcriptional start sites and promoter structure of the
sarV gene. To determine the transcriptional start site and the
promoter sequence, primer extension was performed with total
RNA isolated from the wild-type strain RN6390 and its iso-
genic sarA mutant (data not shown). The transcriptional start
site was mapped to an A or T which was located 62 or 63 bp
upstream of the initiation codon ATG. Based upon the tran-
scriptional start site, the predicted putative promoter boxes are
TAGATA(35)-N17-TATAAT(10), which has close homol-
ogy with the 10 and 35 consensus sequences of A-depen-
dent promoters (Fig. 2A; see also Fig. 4D). A strong ribosome
binding site, AGGAGG, was located 9 bp upstream of the
ATG translational start codon. Analysis of the downstream
sequence of the sarV gene disclosed the presence of a rho-
independent transcriptional terminator sequence from the
position 1 to 91 bp immediately after the stop codon (TAA).
Within this region, a 23-bp inverted repeat sequence from
positions 1 to 23 and 68 to 91 after the stop codon of the sarV
gene (AAAAATAAAAAGCATGCCAATCT-N45-AGATTG
GCATGCTTTTTAAGTTTTT) could form a potential hair-
pin structure with a 24-nt-long heteroduplex.
sarV promoter-gfpuvr fusion studies in isogenic sarA and
mgrA strains. To confirm the repression of sarV by mgrA and
sarA, we constructed a transcriptional fusion containing a 268-
bp sarV promoter fragment upstream of the gfpuvr reporter
gene (Fig. 2A). The construct pALC2489 was introduced into the
wild-type strain RN6390, sarA mutant (ALC1342), mgrA mu-
tant (ALC2530), sarV mutant (ALC2319), sarA/mgrA double
mutant (ALC2535), complemented mgrA mutant (ALC2531),
and complemented sarA mutant (ALC1629). Promoter activi-
ties, assayed as GFPuvr fluorescence (Fig. 2B), were 5-, 13- to
17-, and 18- to 28-fold higher at the three time points for sarA
(lane 3), mgrA (lane 5), and sarA/mgrA (lane 7) mutants, re-
spectively, compared with that of the parental strain RN6390
(lane 1). Complemented sarA and mgrA mutant strains (Fig.
2B, lanes 4 and 6) had reduced GFPuvr values compared to the
parental strain. These data are consistent with the notion that
the expression of sarV gene transcript is repressed by sarA and
mgrA gene products. In the double sarA/mgrA mutant (Fig. 2B,
lane 7), the mean GFPuvr value was higher than that for the
single mutant, indicating that SarA and MgrA may repress
sarV gene expression via divergent mechanisms. Collectively,
these data concur with those of Northern analysis, essentially
demonstrating that the expression of sarV gene transcript was
undetectable in the wild type, moderately elevated in the sarA
mutant, and highly expressed in the mgrA mutant. The expres-
sion of sarV is probably not dependent on its own gene prod-
uct, as the mean GFPuvr value (228 to 407  75 U) in the sarV
mutant was comparable to that for the parental strain RN6390
(176 to 322  50 U).
Binding of SarA and MgrA proteins to the sarV promoter
region. As the level of transcript of sarV was increased in sarA
and mgrA mutants (Fig. 1), we speculated that SarA and MgrA
may bind to the sarV promoter region to modulate sarV ex-
pression. In previous studies, we reported that members of the
SarA protein family (e.g., SarA, -R, -S, and -T) have a con-
served helix-turn-helix motif commonly found in DNA binding
proteins (10, 30, 31). The MgrA protein, as a MarR homolog
and to a lesser extent SarA, likely possesses a helix-turn-helix
motif and hence is predicted to be a DNA binding protein. To
verify this, we employed a 268-bp or a 191-bp sarV promoter
fragment (position 21 to 288 or 21 to 211 nt upstream of the
initiation codon) upstream of the ribosomal binding site for
DNA binding assays. The DNA fragment (0.1 ng or 0.56 fmol
per reaction mixture) was end labeled with [-32P]ATP and
used in gel shift assays with various amounts of purified SarA
and MgrA proteins (Fig. 3). Retarded protein-DNA complex
could be detected with as little as 0.1 to 0.2 g of MgrA (2.8 to
5.7 nM, assuming that MgrA is a dimeric protein like SarA or
SarR) and 0.3 g (10 nM) of SarA. As the concentrations of
these proteins increased, the retarded protein-DNA complex
became the predominant band, with complete conversion at
FIG. 1. Northern analysis of the sarV and mgrA transcripts in the wild type, various isogenic mutants, and complemented strains at postexpo-
nential phases (OD650, 1.7) of growth. A total of 15 g of cellular RNA was loaded onto each lane. The blots were probed with 360-bp sarV
(upper panel), 565-bp mgrA (middle panel), and 724-bp (lower panel) fragments containing the entire ORF of the sarV and mgrA genes and
internal region of 16S rDNA, respectively. cp indicates complementation with respective genes. The OD650 was determined with a spectropho-
tometer (Spectronic 20).
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1.0 g for both proteins. Hence, SarA and MgrA proteins
can bind to the sarV promoter region, presumably acting as a
repressor to sarV transcription. To verify the DNA binding
specificity and to map the binding sites, we performed DNase
I protection assays with the same 268- or 191-bp sarV promoter
fragment labeled with -32P at one end in the presence of SarA
or MgrA (Fig. 4). As shown in Fig. 4A, protection from DNase
I digestion with SarA was mapped to a region 2 to 42 bp
from the 1 transcription start in Fig. 4D. A close analysis of
this sequence revealed that the protected regions (box I, 21
to 42 bp from the transcription start; box II, 2 to 19 bp
from transcription start in Fig. 4D) closely resemble the SarA
FIG. 2. Promoter activation of the sarV promoter fused to a gfpuvr reporter gene. (A) Graphical representation of the 268-bp sarV promoter
fragment fused to a promoterless gfpuvr gene with an S. aureus ribosome binding site. The translational start site, labeled as 1, was identified by
primer extension, and the putative promoter 10 and 35 boxed sequences are also indicated. The numbers at the line (both top and bottom)
are marked according to the transcriptional start site and the translation start codon of the sarV gene, respectively. (B) The recombinant shuttle
construct pALC2489 containing the 268-bp sarV promoter fragment driving the GFPuvr reporter gene was introduced into the wild type, its isogenic
mutant strains, and complemented strains. Lane 1, wild-type RN6390; lane 2, sarV mutant ALC2319; lane 3, sarA mutant ALC1342; lane 4, the
sarB fragment (28) integrated into the geh locus of the sarA mutant designated ALC1629; lane 5, mgrA mutant ALC2530; lane 6, the 1.5-kb DNA
fragment containing the mgrA gene integrated into the geh locus of the mgrA mutant designated ALC2531; lane 7, mgrA sarA double mutant
ALC2539. To minimize variations in fluorescence attributable to cell density, the data are presented as the average of reported fluorescence unit
per OD650 in triplicate samples obtained at different growth points.
FIG. 3. Autoradiogram of an 8.0% nondenaturing polyacrylamide gel showing gel shifts for purified MgrA and SarA proteins with a 268-bp sarV
promoter fragment. Mobility of the DNA band in the presence of increasing amounts of either MgrA or SarA protein is indicated on the top. Cold
competition lanes with a 10-fold excess (molar ratio) of the unlabeled 268-bp sarV fragment are indicated and contained 1.0 g of the purified
MgrA or SarA protein.
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consensus DNA binding motif (ATTTGTATTTAATATTTA
TATAATTG) previously reported by our investigators (10).
Box I and II have 15 of 26 and 19 of 26 matches to the SarA
consensus binding sequence, respectively, thus verifying that
the DNA binding site of SarA on the sarV promoter is likely
specific and further confirming our group’s earlier studies
on the predicted SarA binding consensus sequence. We also
mapped the DNA binding site of the MgrA protein on the sarV
promoter. Using the same end-labeled 191-bp promoter frag-
ment, we initially failed to identify any protected region with
FIG. 4. DNase I protection footprint analysis of SarA and MgrA binding to the sarV promoter region of S. aureus. (A) Footprint analysis of SarA
binding to the sarV promoter region. The 191-bp fragment (nt positions 21 to 211 from the start codon ATG) was end labeled (top or coding strand)
with [-32P]ATP. Lanes 1 and 6, no protein added; lanes 2 to 5, 1, 2, 3, and 4 g of SarA, respectively. Lane M represents chemical cleavage at purine
residues (A/G ladder). (B and C) Footprinting analysis of the MgrA protein binding to the 268-bp sarV promoter region (nt positions 21 to 288 from the
ATG start codon). The 268-bp fragment was end labeled for top strand (B) and bottom strand (C) and incubated with DNase I in the presence or absence
of proteins, as described above. No protein was added for lanes 1 and 6 in panel B or for lanes 1 and 7 in panel C. Lanes 2 to 5 (B) and 4 to 6 (C), 0.2,
0.5, 1.0, and 2.0 g of protein was added; lane 3 of panel C, 0.3 g of protein was added. Protected regions are marked by solid lines. (D) Nucleotide
sequence of the 293-bp fragment upstream of the sarV gene was shown and marked with the putative promoter region and start site as derived from
primer extension data. The putative protected regions for SarA and MgrA proteins on the promoter are marked.
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both strands (data not shown). However, when the assays were
repeated with the larger 268-bp sarV promoter fragment that
we have used for the gfpuvr fusion assay (position 21 to 288
bp from the start codon), we found two closely associated
protected regions (Fig. 4B and C). The putative protected
regions of MgrA are from positions 84 to 115 bp, 132 to
147 bp (Fig. 4B, top strand of DNA), and 81 to 108 bp
upstream of the transcriptional start site (Fig. 4C, bottom
strand of DNA, and D). DNA sequence analyses of these
regions disclosed a 6-bp conserved sequence (t/aGTTGT) that
was repeated four times in the top and bottom strands of the
protected sequence (Fig. 4D). The sequence encompassing
84 to 115 bp upstream of the initiation codon was of in-
terest as it contained the sequence t/aGTTGT thrice and was
protected in both strands. This led us to speculate that MgrA
may bind to this region to facilitate binding to other areas
via conformational changes (e.g., by cooperating interaction,
bending, or other means of regulation). Whether the con-
served 6-bp binding region of MgrA applies to other target loci
regulated by MgrA requires additional confirmation. Never-
theless, the results presented in Fig. 3 and 4 clearly demon-
strated that SarA and MgrA proteins are likely to bind to
different sites on the sarV promoter region with a high degree
of specificity. The SarA binding sites overlap with the 10 and
35 promoter boxes, whereas the MgrA binding sites are up-
stream of the sarV promoter boxes.
Transcription and transcriptional fusion assays for regula-
tory genes in a sarV mutant and various other isogenic strains.
To determine whether inactivation of sarV affects other regu-
latory genes involved in virulence, we performed Northern blot
analysis with 11 other regulatory loci (agr RNAII, agr RNAIII,
sarA, sarR, sarS, sarT, sarU, mgrA, rot, sae, lytS, lytR, arlR, and
arlS). The functions of many SarA homologs have previously
been described, including SarR as a regulator of SarA and agr
expression, SarS as an activator of protein A expression, SarT
as a repressor of -hemolysin expression, and SarU as an
activator of RNAIII that is repressible by SarT (9, 30, 31, 41).
The lytSR locus is a two-component regulatory system that
negatively controls extracellular murein hydrolase activity via
positive regulation of the lrgAB operon (6, 16). An arlRS mu-
tant up-regulates the expression of autolysis genes while aug-
menting transcription of agr and other exoprotein genes, in-
cluding those of extracellular serine protease activity and the
multidrug resistance transporter gene norA (12, 13). The saeRS
locus encodes another two-component regulatory system that
positively regulates the expression of - and -hemolysins,
DNase I, coagulase, and protein A (15). As shown in Fig. 5A,
there was a partial reduction in RNAII and, to a lesser extent,
RNAIII expression during the postexponential phase in the
sarV mutant. Likewise, the levels of transcripts of lytSR and
arlRS were also reduced in the sarV mutant. In contrast, the
transcription levels of sarR, saeRS, sarA, sarS, sarT, rot, and
sarU were not significantly altered in the sarV mutant (data not
shown). However, it should be stressed that the expression of
sarS, sarT, and sarU was difficult to detect even in the parental
strain under routine laboratory culture conditions. Comple-
mentation of the parent and sarV mutant with a plasmid car-
rying the sarV gene either augmented or restored agr RNAII,
agr RNAIII, lytSR, and arlRS transcripts to near or above
parental levels in the recipient strain. Collectively, these data
suggested that sarV might act as an activator either directly or
indirectly for the expression of agr, lytSR, and arlRS.
To verify reduction of agr RNAII, agr RNAIII, arlS, and lytR
transcripts in the sarV mutant (ALC2319), we introduced into
the isogenic sarV strains plasmids containing the agr RNAII,
agr RNAIII, arlS, or lytR promoter linked to the gfpuvr gene for
promoter fusion analysis. Upon monitoring bacterial growth
and serial GFP expression over a 10-h period, we found that
the growth rates were comparable between the two strains
containing each of the constructs, with early stationary phase
appearing after 6 h of growth. The expression of RNAII and
RNAIII during the stationary phase was slightly lower in the
sarV mutant than in the parental strain (Fig. 5B and C). Thus,
both Northern blotting and transcriptional fusion assays were
consistent with the slight reduction of levels of transcripts in
agr RNAII and RNAIII expression in the sarV mutant relative
to that in the parental strain. Similarly, the expression of arlS
promoter-gfpuv and lytR promoter-gfpuv was found to be re-
duced approximately threefold in the sarV mutant compared to
the wild-type strain after 8 h of growth (Fig. 5D). Hence,
Northern and transcriptional fusion studies suggested that the
sarV gene product possibly acts as an activator for the expres-
sion of agr, arlRS, and lytSR transcripts. These results were
consistent in several repeated experiments. Whether this effect
is direct or indirect and also physiologically relevant remains to
be determined.
Northern blot analysis for the expression of target genes.
The data presented above clearly indicated that the expression
of sarV, normally undetectable in the parental strain, was ele-
vated moderately in the sarA mutant and highly in the mgrA
mutant. SarA and MgrA, as DNA binding proteins, bind to the
sarV promoter region, presumably to repress sarV transcrip-
tion. As sarA and mgrA participate in the control of autolysis as
well as virulence genes (4, 8, 10, 12, 17, 26, 45), we determined
the expression of target genes known to be involved in autolysis
or virulence in the sarV mutant. We tested the expression of 19
potential target genes (33), with 11 genes implicated in viru-
lence (e.g., hla, coa, geh, splA, scp, norA, aur, spa, clfA, fnbA,
and fnbB) and 8 involved in autolysis (lytN, lytM, atl, lrgB, scdA,
abcA, pbp2, and pbp4). The transcript levels of genes encoding
many cell surface-associated proteins (fnbA, fnbB, clfA, and
spa) were not markedly altered by the sarV mutation during
exponential and postexponential phases of growth (data not
shown). The expression levels of geh (glycerol ester hydrolase)
and coa (coagulase) were also not significantly affected in the
sarV mutant (data not shown). The transcript level of the hla
gene was lower in the sarV mutant compared with that in the
parental strain but was restored upon complementation (Fig.
6). Transcriptional fusion of hla-gfpuvr also supported the
Northern blotting data (1,185  250 versus 2,278  500 mean
fluorescence units per OD at 6 h of growth for the sarV mutant
and parent strain, respectively). A significant reduction in tran-
scripts levels of splA, encoding a putative serine protease-like
gene product, aur, encoding a zinc metalloprotease, and scp,
encoding staphopain (protease II) (19, 39) was observed in the
sarV mutant, while transcripts levels of these genes were sub-
stantially elevated in the parental strain or returned to a near-
normal level in the mutant harboring trans-complementation
of the sarV gene in multicopy (Fig. 6). As predicted from
earlier findings, the agr mutant also displayed a significant
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reduction in these proteases, while a sarA mutation led to an
increase in the expression of these transcripts (19, 39).
The level of transcript of scdA, a gene positively associated
with decreasing peptidoglycan cross-linking and increased au-
tolysis (7), and the autolysin gene atl, which encodes major
autolysin (34, 36, 40), was found to be decreased in the sarV
mutant, thus suggesting positive regulation of scdA and atl by
sarV gene; complementation of the sarV mutant with a multi-
copy plasmid (ALC2376) increased the expression of scdA or
atl in the mutant, but the effect was only partial, thus suggest-
ing that regulation of these genes by sarV may possibly be
indirect or via some unknown factor. Interestingly, a sarA mu-
tation increased scdA and atl transcripts, while agr inactivation
did not have any significant change (Fig. 6). The abcA gene,
encoding an ATP binding cassette transporter, is divergently
transcribed from pbp4 (encoding penicillin binding protein 4)
and is associated with cell autolysis (42). Interestingly, inacti-
vation of sarV augmented the lrgB transcript level (Fig. 6),
while a sarA mutant also increased lrgB transcription, consis-
tent with S. aureus gene array analysis (DNA chip) data (11).
Northern analysis revealed little or no impact effect of sarV on
abcA expression. In contrast, an agr mutant, but not a sarA
mutant, displayed a significant reduction in abcA transcript
level, in concordance with the data of Schrader-Fischer and
Berger-Bachi (42). Under our experimental conditions, the
pbp4 transcript was found to be undetectable in the isogenic
sarV strains. Additionally, there was no significant difference in
norA, pbp2, lytN, and lytM transcript levels attributable to the
sarV mutation (data not shown). Thus, a mutation in sarV led
to a reduction in transcript level of atl, the major autolysin, as
well as an alteration in scdA and lrgB expression profiles con-
sistent with an autolysis-resistant phenotype.
Phenotypic characterization of the sarV gene. The alteration
in atl, lrgB, and scdA expression levels of transcripts in the sarV
mutant, coupled with the repressive effect on sarV by mgrA and
sarA, suggested that sarV may play an important role in con-
trolling autolysis mediated by mgrA and sarA in S. aureus. Ac-
cordingly, we tested the sarV mutant for susceptibility to lysis in
FIG. 5. Analysis of assorted regulatory genes in a sarV mutant. (A) Northern blots of agr RNAII and RNAIII, lytR, arlS, and 16S rRNA
transcripts in the wild-type RN6390, sarV (ALC2319), trans-complemented strains (ALC2375, ALC2376), and sarA (ALC1342) and agr (RN6911)
mutants. A total of 10 g of RNA from the postexponential phase (OD650, 1.7) was applied to each lane, and the blots were probed with the
respective gene fragment containing the coding region. (B to D) GFPuvr expression as driven by agr RNAII (B), agr RNAIII (C), and arlS-gfpuv
and lytR-gfpuv (D) promoters in the wild-type RN6390 and sarV mutant ALC2319. Bar diagrams in panels B and C represent various time points,
whereas in panel D the diagram represents the 8-h time point. The experiments were repeated at least thrice; one representative experiment is
shown.
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the presence of a detergent and an antibiotic. As shown in Fig.
7A, the sarV mutant was more resistant to Triton X-100-in-
duced lysis in 50 mM Tris-Cl buffer, pH 7.2, than the wild-type
RN6390 strain. The buffer alone also induced lysis of the wild
type, and this effect was amplified by 0.05% Triton X-100. In
contrast, the sarV mutant strain remained less susceptible in
the buffer. Interestingly, the parental strain carrying the sarV
gene on multicopy plasmid (ALC2375) became slightly more
lytic than the wild-type strain in the presence of Triton X-100.
Similarly, the sarV mutant carrying the sarV gene on multicopy
FIG. 6. Northern blot analysis for assorted target genes in the wild type, sarV mutant (ALC2319), trans-supplemented strains ALC2375 and
ALC2376, sarA mutant ALC1342, and agr mutant RN6911. Northern blots were hybridized with hla, splA, aur, scdA, lrgB, atl, abcA, and 16S rRNA
DNA fragments containing the coding regions of the respective genes. A total of 10 g of RNA from the postexponential phase (OD650, 1.7)
was applied to each lane, and the OD650 was determined with a spectrophotometer (Spectronic 20).
FIG. 7. Phenotypic and trans-functional analysis of the sarV gene. (A) Effect of the sarV mutation on Triton X-100-induced autolysis. { and
}, wild-type S. aureus strain RN6390;  and ■ , sarV mutant ALC2319; ‚ and Œ, wild-type strain containing trans-supplemented sarV gene in
multicopy plasmid pSK236, ALC2375; E and F, sarA mutant strain ALC488. Strains were grown as described in Materials and Methods, with
0.05% Triton X-100 (open symbols) and without Triton X-100 (filled symbols), following the decline of A650 as an indicator of lysis. (B) Effect of
sarV on penicillin-induced autolysis. Penicillin G-induced autolysis of wild-type RN6390 ({), sarV mutant ALC2319 (), RN6390 containing
trans-supplemented sarV gene, ALC2375 (	), agr mutant RN6911 (■ ), and sarA mutant ALC1342 (F) was measured as the decline in culture
turbidity versus time. Autolysis is expressed as the percent of the initial OD650 reading immediately before penicillin was added. The experiments
were repeated at least thrice; one representative experiment is shown.
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plasmid (ALC2376) was more susceptible to lysis, but slightly
less than its wild-type counterpart (data not shown). We also
tested the effect of sarV on penicillin-induced lysis. Penicillin G
(0.4 g/ml) was added to a growing culture at early exponential
phase (OD650  0.5), and changes in optical density (OD650),
as a percentage of initial absorbance (OD), were monitored
over a 7-h period. As shown in Fig. 7B, the parental strain
RN6390 exhibited sensitivity to penicillin-induced lysis while
the sarV mutant was resistant, resulting in an OD higher than
that of the starting culture even at 6 h after the addition of
penicillin. As a positive control, the sarA and agr mutants dis-
played high and low sensitivities, respectively, to penicillin-
induced lysis, consistent with previously published data (14, 27).
To determine whether the lytic resistance phenotype was
attributable to variations in murein hydrolase activity, possibly
due to decreased expression of atl or scdA and/or enhanced
expression of lrgB, zymographic analyses of culture superna-
tants and intracellular proteins of various strains were per-
formed using gels containing M. luteus or S. aureus cells to
detect glucosaminidase (GL) (Fig. 8A and B) and amidase
(AM) (Fig. 8C and D) activities, respectively. It is known that
atl (autolysin) is expressed as a 138-kDa precursor protein that
is processed by protease to yield GL and AM domains of 54
and 63 kDa, respectively (34). Comparison between various
strains revealed that the culture supernatant of the sarV mu-
tant (ALC2319) displayed decreased GL (Fig. 8A) and AM
(Fig. 8C) activities compared to the wild-type RN6390 strain.
Significantly, no GL and AM activities were detected in super-
natant of an atl mutant, JC1413 (Fig. 8, lanes 6). The intracel-
lular proteins of the sarV mutant showed no significant varia-
tion of GL activity in the 54-kDa-size region (Fig. 8B) or AM
activity in the 63-kDa-size region (Fig. 9D), but there was an
extra zone of hydrolysis for both activities in the 97-kDa-size
region compared to results with RN6390. We speculated that
the appearance of this band was due to the unprocessed auto-
lysin, which is yet to be confirmed. The cell wall-associated
proteins of the sarV mutant also showed similar types of vari-
ation of the GL and AM activities as were found for intracel-
lular proteins (data not shown). The variation in autolytic
activity of autolysin is controlled by multiple factors that in-
clude SspA/V8 serine protease, SspB/cysteine protease, lrgAB
operon/speculated holin and antiholin, another regulatory lo-
cus, and or an undefined regulatory mechanism (37). We also
speculated that various other proteases, like aur, splA, and scp,
which are decreased in a sarV mutant, might be involved in the
resistance of autolysis.
To quantify the zymographic analysis, cell wall hydrolysis
assays were performed as described by Rice et al. (38). Culture
FIG. 8. Zymographic analysis of various fractions of different S. aureus strains. Extracellular proteins (A and C) and intracellular proteins (B
and D) were isolated, and various amounts were loaded onto an SDS–12% polyacrylamide gel containing 1.0 mg of either M. luteus (A and B) or
heat-killed RN6390 cells/ml, resolved, and treated with a buffer containing 1% Triton X-100, followed by staining with 1% methylene blue. Lanes
1 and 2, 2 and 4 g of extra- or intracellular proteins of RN6390 strain; lanes 3 to 5, 2, 4, and 6 g of extra- or intracellular proteins of the sarV
mutant (ALC2319); lane 6, 4 g of extra- or intracellular proteins of the atl mutant (JC1413). Molecular size markers in kilodaltons are indicated
to the left of each gel.
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supernatants (100 g) were added to a suspension of M. luteus
cells (1.0 mg per ml) in 100 mM Tris-Cl (pH 8.0) and incubated
at 37°C with shaking, and the turbidity of the samples was
monitored at 580 nm. As shown in Fig. 9, the extracellular
murein hydrolases of ALC2319 caused no significant decrease
in turbidity of M. luteus cells after 8 h of incubation, compared
to about a 35% decrease in turbidity with the wild-type
RN6390 extracellular murein hydrolases. In contrast, the pres-
ence of the sarV gene in multicopy plasmid in the wild-type
RN6390 caused about a 40% decrease in turbidity after 8 h.
These results, along with the zymographic analysis, demon-
strate that inactivation of the sarV gene results in a reduction
in the extracellular murein hydrolase activity produced by
S. aureus.
DISCUSSION
In prior studies, we and others have characterized SarA-like
proteins, including SarA (SA0573), SarR (SA2089), SarS
(SA0108; SarH1), Rot (SA1583), SarT (SA2286; SarH2), and
SarU (SA2287; SarH3), that are involved in the regulation of
virulence genes in S. aureus. Similar to SarA, SarV has se-
quence similarity to other SarA homologs, such as SarA, SarR,
SarT, and Rot, and also to those with two homologous halves,
such as SarS and SarU (data not shown). Unlike MgrA, SarV
has a lower degree of sequence similarity to MarR-like pro-
teins (e.g., 20% identities with MarR-like proteins of B.
subtilis and Xanthomonas axonopodis). Despite this finding,
there are specific residues with the protein sequence that are
conserved, similar to those found with members of the SarA
protein family (see below).
We recently solved the winged-helix structure of SarR, a
member of the SarA protein family (24). The dimeric wing-
helix structure of SarR is a three-domain structure containing
a central helical core and two winged-helix motifs. Each of the
winged-helix motifs encompasses a helix-turn-helix motif (res-
idues 52 to 73) and a -hairpin turn (residues 80 to 95), with
both predicted to be DNA binding domains, based upon se-
quence alignment (23). Interestingly, many of the basic resi-
dues are conserved within members of the SarA protein family,
consistent with the notion that the DNA binding domains
might be highly conserved within this protein family. Indeed,
detailed mutational analysis of SarR indicates that many of the
conserved residues (e.g., K52, K80, R82, R88, etc.) are in-
volved in DNA binding (A. C. Manna et al., unpublished data).
The structures of MarR in E. coli and SarS in S. aureus were
recently solved and were found to be variants of the dimeric
winged-helix structure, both containing features that are dis-
tinct from SarR (1, 23). Based on structures and sequence
alignment, we propose to classify the SarA protein family into
three subfamilies: (i) the single-domain proteins (e.g., SarR
and SarV); (ii) the two-domain proteins (e.g., SarS and SarU);
and (iii) single-domain proteins that are homologous to MarR
(e.g., MgrA and its homologs). We predict that members
within the same subfamily likely posses similar structures with
common DNA binding domains and a divergent activation or
repression domain.
The transcription of sarA-like genes is highly variable in
strain RN6390. For instance, sarA, sarR, and mgrA transcripts
are highly expressed in the parental strain, whereas the tran-
scription of sarU, sarT, and sarS is not readily detectable under
normal laboratory growth conditions. We also found the sarV
gene to be poorly transcribed in the parental strain. Northern
analyses of agr, sarR, sarT, sarU, and sarS mutants revealed
transcription of the sarV gene to be low in these mutants but at
a high level in the sarA mutant and more so in the mgrA
mutant. The effect of a sarA mutation on sarV transcription was
also supported by similarly increased mean GFPuvr values in
the sarV promoter-gfpuvr fusion analysis in three different sarA
mutant strains in our laboratory (data not shown). The finding
that the mgrA transcript was elevated in the sarV-supple-
mented parent and sarV mutant strains (Fig. 1) suggested the
plausibility of a feedback loop on mgrA expression by the sarV
gene, possibly to fine-tune mgrA expression. This result was
also supported by promoter fusion studies (mgrA P1 promoter-
gfpuvr) in a pair of isogenic sarV strains, documenting a sub-
stantial reduction in mean GFPuvr fluorescence in the sarV
mutant ALC2319 (7,996  750 units per OD650) compared the
wild-type RN6390 (11,775  1,000 units per OD650). However,
the applicability of this magnitude of increased sarV gene dos-
age to augment mgrA transcription under in vivo conditions
was not defined in this study.
In gel shift studies (Fig. 3), we found that purified SarA and
MgrA proteins formed complexes with the sarV promoter with
fairly high affinity. As protein-DNA complexes are shifted sub-
stantially, we speculate that multiple SarA or MgrA dimers
might interact with each other to bind to the sarV promoter
region. This is based on our modeling data, showing that three
SarA dimers are needed to bind to a single 135-bp agr pro-
moter fragment (unpublished data). The specificity of the SarA
and MgrA proteins was determined by DNase I footprinting.
Two SarA binding regions (box I and II) were found within the
268-bp sarV promoter sequence, locating and overlapping with
the 10 and 35 region of the sarV promoter. Interestingly,
each of these two binding regions resembles the SarA consen-
FIG. 9. Quantitative murein hydrolase assays of the sarV mutant.
Aliquots of 100 g of the extracellular proteins of various strains were
added to a suspension of M. luteus cells (1.0 mg per ml), and turbidity
was monitored for 8 h. Strains used for quantitative hydrolase analysis
were the wild-type RN6390 ({), sarV mutant ALC2319 (), and the
wild-type strain containing trans-supplemented sarV in multicopy plas-
mid pSK236, ALC2375 (Œ). 
, control in which no extracellular pro-
tein was added to the cell suspension. These data are from a single
representative experiment and were reproduced several times. OD was
determined at 580 nm with a spectrophotometer (Spectronic 20).
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sus binding motif or the SarA box, previously reported by our
group (10). In contrast, the MgrA protein has binding regions
outside of the promoter boxes that are distinct from the SarA
binding site. These findings are consistent with the notion that
MgrA and SarA may repress sarV via divergent mechanisms.
Using DNA gene chip technology, Dunman et al. (11) have
demonstrated that agr and sarA regulate the expression of over
100 genes, including known virulence factors as well as other
genes involved in metabolism and/or autolysis. Many of the
known virulence genes are controlled by regulators like agr,
sarA, sarA homologs, sae, and arlRS. Inactivation of the sarV
gene has a partial effect on the expression of agr, lytSR, arlRS,
and mgrA, while the effects on sae, sarA, sarR, sarT, sarS, rot,
and sarU are minimal. However, the physiological relevance
and the mechanism by which the sarV gene product, normally
undetectable or at a very low level in the wild type under
laboratory conditions, acts as a positive regulator (e.g., agr) are
not clear from these studies.
Interestingly, sarV does not have any significant effect on cell
surface proteins such as protein A (spa), FnbA and -B, and
clumping factor A. The regulation of secreted proteins by sarV
entails up-regulation of hla, splA, and aur, concordant with the
notion that sarV regulates agr. The repression of the sarV gene
by mgrA and sarA suggests that the sarV gene product may play
a regulatory role in cell lysis, since both mgrA and sarA nega-
tively control genes involved in autolysis, presumably by up-
regulating murein hydrolase activity in respective mutants. Re-
markably, lytic assays revealed that the sarV mutant was more
resistant to the lytic effect of Triton X-100 and penicillin G.
Surprisingly, an examination of regulatory genes (i.e., lytSR
and arlRS) known to repress murein hydrolase activity dis-
closed down-regulation of these genes in the sarV mutant (Fig.
5 and 6). However, other genes (i.e., scdA and atl [Fig. 6]),
positively linked to increase autolysis, were down-regulated in
the sarV mutant, exactly what one would expect in a strain less
prone to autolysis. The expression of lrgB, a part of the lrgAB
operon, which negatively controls the autolysis process, was
substantially higher in the sarV mutant than in the parent.
Whether lrgB may be directly involved in the lytic-resistant
phenotype of the sarV mutant was not clearly defined in our
study. Because atl, scdA, aur, splA, and scp expression levels are
altered in the sarV mutant, we speculate that sarV might, at
least in part, render S. aureus cells more susceptible to cell lysis
via a mechanism distinct from mgrA or sarA. Recently, a two-
component system, vraSR, has been shown to positively regu-
late the cell wall-associated biosynthesis genes. DNA microar-
ray analysis of S. aureus N315 and a vraSR mutant treated with
vancomycin revealed that vancomycin induces transcription of
139 genes, and SA2062 (sarV) is one of them, up-regulated
about 4.2-fold in both strains (22). These data supported our
finding that sarV is an important transcriptional regulator and
is involved in the regulation of the virulence and autolysis
genes. Collectively, these data indicate that sarV impacts neg-
atively upon the expression of proteases (aur, splA, and scp), an
autolysin (atl), and a gene involved in peptidoglycan cross-
linking (scdA). These phenotypic alterations would account for
the autolysis-resistant phenotype of the sarV mutant and the
sensitivity of the sarV-hyperexpressing strains to autolysis. In-
terestingly, zymogram analysis revealed that the sarV mutant
has a different profile from that of an atl mutant (Fig. 8), thus
indicating that reduced atl expression alone cannot account for
the autolysis-resistant phenotype of the sarV mutant. The facts
that sarV is repressed by negative regulators of autolysis such
as MgrA and SarA and that the sarV mutant displays a diver-
gent autolytic phenotype from mgrA and sarA mutants indicate
that SarV is likely an important regulator controlled by mgrA
and sarA to modulate cell lysis.
To further define the precise function of the sarV gene
product, we are in the process of constructing various knock-
outs of sarV with other regulatory genes, particularly with sarA
and mgrA, and investigating the molecular interaction of SarV
with the upstream region of its target genes. Analysis of a sarV
knockout in combination with mutations in sarA, mgrA, and
other regulatory genes, coupled with our studies on the struc-
ture-function relationship of these proteins, may provide a
clearer understanding of the mechanism of gene regulation
by SarV and other SarA homologs. By unveiling the precise
knowledge of these mechanisms and how they control viru-
lence gene expression, this might open up new perspectives for
antimicrobial chemotherapy using key inhibitors of these sys-
tems.
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